Augtyro (repotrectinib), which first got a green light from the FDA as a treatment for ROS1-positive non-small-cell lung cancer (NSCLC) last November, has now had its label extended to include all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback